

BOARD AND MANAGEMENT CHANGES

- **PYC Therapeutics is preparing for the future growth of the organisation with changes to its Board and Executive management team**
- **Dr. Rohan Hockings has committed to guide the Company through its critical upcoming human efficacy window expected to be the end of 2027**
- **Board changes (all with immediate effect):**
 - **Dr. Hockings has been re-appointed as Managing Director of the Company**
 - **Prof. Ian Constable has been appointed Non-Executive Director of the Company**
 - **Dr. Michael Rosenblatt and Mr. Jason Haddock have resigned from their roles as Non-Executive Directors of the Company**
- **Management changes**
 - **Dr. Hockings will resume management of the Company's operations from Mr. Alan Tribe**
- **Future changes**
 - **PYC will build out both the Board and Executive management team over the coming months to prepare for the substantial growth ahead as the Company progresses multiple drug candidates with disease-modifying potential into late-stage clinical development**
 - **The Company will update investors on these appointments as they are implemented**

PERTH, Australia and SAN FRANCISCO, California – 22 September 2025

PYC Therapeutics (ASX:PYC) (PYC or the Company) today announces changes to its Board and Executive management team designed to support the Company deliver its near-term growth ambitions. Dr. Rohan Hockings has been re-appointed Managing Director of the Company and will resume responsibility for progressing the Company's pipeline of drug candidates with disease-modifying potential through critical near-term human safety and efficacy read-outs.

Prof. Ian Constable has been appointed as a Non-Executive Director of the Company to provide access to his deep knowledge of the clinical development, regulatory engagement and commercialisation activities required in support of the development of novel therapeutics.

Prof. Ian Constable AO was the Foundation Lions Professor of Ophthalmology at the University of Western Australia, Foundation Chair of the Australian Association of Ophthalmology and Visual Science, and Founding Managing Director of the Lions Eye Institute Limited. Professor Constable is a practising ophthalmologist with extensive experience in the development of new drugs from discovery through to commercialisation. Professor Constable is a member of the

Advisory Board of the Lowy Medical Research Institute based in San Diego and Chair of the Scientific Advisory board of the Snow Vision Accelerator.

US based Directors Dr. Michael Rosenblatt and Mr. Jason Haddock have resigned from their roles as Directors of the Company with immediate effect. The Board of PYC would like to thank Dr. Rosenblatt and Mr. Haddock for their contributions to the Company over the past 4 years - overseeing the progression of PYC to a clinical-stage biotechnology company.

PYC will continue to build out both its Board and Executive management team over coming months as it progresses its pipeline of drug candidates into late-stage clinical development. The Company is preparing for a period of substantial growth and these changes will support the progression of multiple concurrent clinical development programs. Further details will be provided as these changes are implemented.

The Board of PYC now comprises:

Mr Alan Tribe (Chair)

Dr Rohan Hockings (Managing Director)

Prof Ian Constable (Non-Executive Director)

Additional details

The Employment Agreement for Dr. Hockings is summarised in Annexure A to this ASX Announcement, in accordance with ASX Listing Rule 3.16.4.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development ¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact

investor@pyctx.com



ANNEXURE A

Summary of Material Terms of Dr. Hockings' Executive Employment

Commencement date	22 September 2025
Position	Managing Director and Chief Executive Officer
Term	Ongoing until terminated by either party
Fixed Annual Remuneration	\$395,000 per annum (including statutory superannuation)
Short Term Incentive	Payment of up to \$198,000. The performance criteria, assessment and timing are determined at the discretion of the Board.
Notice Period	2 months' notice by the individual. 12 months' notice if terminated by the Company.